Journals / Güncel Retina Dergisi / 2021 / Cilt: 5 - Sayı: 3

Retinopathies with Phacomatoses; Pathophysiology, Findings, Diagnosis and Treatment (Von Hippel-Lindau Disease, Tuberous Sclerosis, Neurofibromatosis)

Fakomatözler İle Birlikte Olan Retinopatiler; Patofizyoloji, Bulgular, Tanı ve Tedavi (Von Hippel-Lindau Hastalığı, Tuberoskleroz, Nörofibromatozis)

Pages
279–285
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, when these lesions are seen in the eyes, it is necessary to treat them with a multidisciplinary approach considering that systemic involvement may occur.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Phacomatosis is the general name for a group of diseases (Neurofibromatosis 1 (NF-1), Neurofibromatosis 2 (NF-2), Von Hippel Lindau, tuberous sclerosis, ataxia telangiectasia and Suturge Weber syndrome) that include different clinical syndromes characterized by eye, skin, neurological and oncological symptoms.
📊
Key Findings & Data:Neurofibromatosis -1 is the most common type of phacomatosis. autosomal dominant passes.
💡
Conclusion & Impact:In conclusion, when these lesions are seen in the eyes, it is necessary to treat them with a multidisciplinary approach considering that systemic involvement may occur.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Phacomatosis is the general name for a group of diseases (Neurofibromatosis 1 (NF-1), Neurofibromatosis 2 (NF-2), Von Hippel Lindau, tuberous sclerosis, ataxia telangiectasia and Suturge Weber syndrome) that include different clinical syndromes characterized by eye, skin, neurological and oncological symptoms. They are formed as a result of tumor suppressor protein loss, which controls the abnormal growth of cells. Most of these diseases are autosomal dominant. Neurofibromatosis -1 is the most common type of phacomatosis. autosomal dominant passes. Skin (cafe au-lait = milk coffee stain, armpit, and inguinal freckles), ocular involvement, and nerve involvement (neurofibromas) are seen. In NF-2, in addition to NF-1, 8th cranial nerve involvement is present. In ocular involvement of neurofibromatosis, proptosis, strabismus, pulsatile exophthalmos, ptosis may occur due to neurofibromas. Hamartomas in iris (lisch nodules), posterior subcapsular cataract (more often in NF-2), retinal astrocytic hamartomas and optic glioma can be seen. Von Hippel Lindau passes autosomal dominant. Brain (cerebellum) spinal cord, renal cell carcinoma, pheochromocytoma, pancreatic neuroendocrine tumors, and renal or pancreatic cysts may occur as systemic involvement. Retinal hemangioblastomas can be seen in ocular involvement. Tuberous sclerosis passes autosomal dominantly. It is a disease in the group of phacomatosis, characterized by hamartomas affecting more than one organ, including the skin, central nervous system, lung, heart, and kidney. Multiple astrocytic hamartomas can be seen in ocular involvement. In conclusion, when these lesions are seen in the eyes, it is necessary to treat them with a multidisciplinary approach considering that systemic involvement may occur.

Özet

Fakomatozis göz, cilt, nörolojik ve onkolojik belirtilerle karakterize farklı klinik sendromları içeren bir grup hastalıkların(Nörofibtomatozis 1 (NF-1), nöfofibromatozis 2 (NF-2), Von Hippel Lindau, tuberosklerozis, ataxia telenjektazi ve Sturgeweber sendromu) genel adıdır. Hücrelerin anormal büyümesini kontrol eden tümör supresör proteinin kaybı sonucu oluşurlar ve bu hastalıkların çoğunluğu da otozomal dominant (OD) geçmektedirler.NF-1 en sık görülen fakomatozis tipidir. Kalıtım şekli OD’dir. Bu hastalıkta cilt (cafe au-lait=sütlü kahve lekesi, koltuk altıve inguinal bölgede çiller), oküler tutulum ve sinir tutulumu (nörofibromlar) görülmektedir. NF-2 de ise NF-1‘e ilaveten 8.kranial sinir tutulumu da mevcuttur. Nörofibromatozisin oküler tutulumunda nörofibromlara bağlı propitozis, şaşılık, pulsatil ekzoftalmus, pitozis oluşabilir. İriste hamartomlar (lisch nodülleri), posterior subkapsüler katarakt (NF-2’de daha sık),retinal astrositik hamartomlar ve optik gliom görülebilir. Von hippel lindau hastalığının kalıtım şekli OD’dir. Bu hastalıktasistemik olarak beyin, spinal kord, böbrek (renal hücreli karsinom, renal kist, feokromasitoma) ve pankreas (pankreatiknöroendokrin tümör, pankreatik kist) tutulumu görülürken oküler tutulum da (retinal hemanjioblastom) görülebilir. Tuberosklerozis ise kalıtım şekli olarak OD geçen, cilt, merkezi sinir sitemi, akciğer, kalp, böbrek dahil olmak üzere birden fazlaorganı etkileyen ve hamartomlarla karekterize fakomatozis grubundaki bir hastalıktır. Oküler tutulumunda multipl astrositik hamartomlar görülebilir. Sonuç olarak gözde bu lezyonlar görüldüğü zaman hastaların sistemik tutulumların olabileceğidüşünülerek multidisipliner yaklaşım ile tedavi etmek gerekir.

🔖

Cite This Article

AVA, S., ERDEM, S. (2021). Retinopathies with Phacomatoses; Pathophysiology, Findings, Diagnosis and Treatment (Von Hippel-Lindau Disease, Tuberous Sclerosis, Neurofibromatosis). Güncel Retina Dergisi, Cilt: 5 - Sayı: 3, 279–285. https://ajindex.com/articles/347955

References (11)

  1. Somlai J. Phacomatoses In Neuro-Ophthalmology: Springer Cham. 2016; 339-344
  2. Kerrison JB. Neuro-ophthalmology of the phacomatoses: Current opinion in ophthalmology. 2000;11(6):413-420
  3. Alkatan, HM., Bakry SS, Alabduljabbar MA. Ocular Findings in Neurofibromatosis: In Neurofibromatosis-Current Trends and Future Directions. IntechOpen. 2019
  4. Savar A, Cestari DM. Neurofibromatosis type I: genetics and clinical manifestations. Semin Ophthalmol. 2008;23(1):45-51 5- Thomann K, Marks E, Adamczyk D. Primary Eyecare in Systemic Disease: 2nd ed. New York: McGraw-Hill. 2001 6- Oystreck DT, Morales J, Chaudhry I, Alorainy IA, Elkhamary SM, Pasha TM,et al. Visual loss in orbitofacial neurofibromatosis type 1: Ophthalmology. 2012;119(10): 2168-2173
  5. Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci. 2012;32(41):14087-14093 8- Avery RA, Katowitz JA, Fisher MJ, Heidary G, Dombi E, Packer RJ, et al. Orbital/periorbital plexiform neurofibromas in children with neurofibromatosis type 1: multidisciplinary recommendations for care. Ophthalmology 2017;124(1):123-132
  6. NİH. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-178 10- De Schepper S, Boucneau J, Lambert J, Messiaen,L, Naeyaert, JM. Pigment cell related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res. 2005;18(1):13-24 11- Abdolrahimzadeh B, Piraino DC, Albanese G, Cruciani, F, Rahimi S. Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography. Clin Ophthalmol. 2016;10:851- 860 12- Ferner RE, Huson SM, Evans DGR. Neurofibromatoses in Clinical Practice: Springer-Verlag, London. 2011
  7. Evans DG. Neurofibromatosis 2: In Pagon RA, Adam MP, Ardinger HH Gene Reviews: University of Washington, Seattle WA. 2011
  8. MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood: Seminars in Pediatric Neurology. 1998;5(4):243- 252
  9. Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngologica Italica. 2016;36(5):345-367
  10. Tsang,S, SharmaT. Neurofibromatosis. In: Atlas of Inherited Retinal Diseases: Springer, Cham. 2018;209-211
  11. Evans D. Medical management of neurofibr